Cargando…

IgE responses to exogenous and endogenous allergens in atopic dermatitis patients under long‐term systemic cyclosporine A treatment

Atopic dermatitis (AD) patients mount IgE antibody responses to a variety of environmental allergens and also to autoantigens. We analyzed serum samples from four AD patients who had received oral cyclosporine A (CyA) treatment for up to 17 months regarding IgE autoreactivity to nitrocellulose‐blott...

Descripción completa

Detalles Bibliográficos
Autores principales: Lucae, S., Schmid‐Grendelmeier, P., Wüthrich, B., Kraft, D., Valenta, R., Linhart, B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4950058/
https://www.ncbi.nlm.nih.gov/pubmed/26234649
http://dx.doi.org/10.1111/all.12711
_version_ 1782443520989069312
author Lucae, S.
Schmid‐Grendelmeier, P.
Wüthrich, B.
Kraft, D.
Valenta, R.
Linhart, B.
author_facet Lucae, S.
Schmid‐Grendelmeier, P.
Wüthrich, B.
Kraft, D.
Valenta, R.
Linhart, B.
author_sort Lucae, S.
collection PubMed
description Atopic dermatitis (AD) patients mount IgE antibody responses to a variety of environmental allergens and also to autoantigens. We analyzed serum samples from four AD patients who had received oral cyclosporine A (CyA) treatment for up to 17 months regarding IgE autoreactivity to nitrocellulose‐blotted human epithelial cell extracts and IgE levels to environmental allergens by quantitative ImmunoCap measurements. Skin inflammation was assessed by SCORAD. During full‐dose treatment, a strong reduction in T‐cell‐mediated skin symptoms was observed which reappeared when CyA treatment was reduced or stopped. The intensity of IgE autoreactivity seemed to follow skin inflammation as it was reduced during full‐dose treatment and increased upon inflammation. Interestingly, IgE levels to exogenous allergens were boosted by allergen exposure, declined thereafter, and seemed to be unaffected by CyA. Our data thus indicate that allergen‐specific IgE production is boosted by allergen contact and cannot be reduced by CyA‐mediated T‐cell suppression.
format Online
Article
Text
id pubmed-4950058
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-49500582016-07-28 IgE responses to exogenous and endogenous allergens in atopic dermatitis patients under long‐term systemic cyclosporine A treatment Lucae, S. Schmid‐Grendelmeier, P. Wüthrich, B. Kraft, D. Valenta, R. Linhart, B. Allergy Brief Communications Atopic dermatitis (AD) patients mount IgE antibody responses to a variety of environmental allergens and also to autoantigens. We analyzed serum samples from four AD patients who had received oral cyclosporine A (CyA) treatment for up to 17 months regarding IgE autoreactivity to nitrocellulose‐blotted human epithelial cell extracts and IgE levels to environmental allergens by quantitative ImmunoCap measurements. Skin inflammation was assessed by SCORAD. During full‐dose treatment, a strong reduction in T‐cell‐mediated skin symptoms was observed which reappeared when CyA treatment was reduced or stopped. The intensity of IgE autoreactivity seemed to follow skin inflammation as it was reduced during full‐dose treatment and increased upon inflammation. Interestingly, IgE levels to exogenous allergens were boosted by allergen exposure, declined thereafter, and seemed to be unaffected by CyA. Our data thus indicate that allergen‐specific IgE production is boosted by allergen contact and cannot be reduced by CyA‐mediated T‐cell suppression. John Wiley and Sons Inc. 2015-09-17 2016-01 /pmc/articles/PMC4950058/ /pubmed/26234649 http://dx.doi.org/10.1111/all.12711 Text en © 2015 The Authors. Allergy Published by John Wiley & Sons Ltd. This is an open access article under the terms of the Creative Commons Attribution (http://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Brief Communications
Lucae, S.
Schmid‐Grendelmeier, P.
Wüthrich, B.
Kraft, D.
Valenta, R.
Linhart, B.
IgE responses to exogenous and endogenous allergens in atopic dermatitis patients under long‐term systemic cyclosporine A treatment
title IgE responses to exogenous and endogenous allergens in atopic dermatitis patients under long‐term systemic cyclosporine A treatment
title_full IgE responses to exogenous and endogenous allergens in atopic dermatitis patients under long‐term systemic cyclosporine A treatment
title_fullStr IgE responses to exogenous and endogenous allergens in atopic dermatitis patients under long‐term systemic cyclosporine A treatment
title_full_unstemmed IgE responses to exogenous and endogenous allergens in atopic dermatitis patients under long‐term systemic cyclosporine A treatment
title_short IgE responses to exogenous and endogenous allergens in atopic dermatitis patients under long‐term systemic cyclosporine A treatment
title_sort ige responses to exogenous and endogenous allergens in atopic dermatitis patients under long‐term systemic cyclosporine a treatment
topic Brief Communications
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4950058/
https://www.ncbi.nlm.nih.gov/pubmed/26234649
http://dx.doi.org/10.1111/all.12711
work_keys_str_mv AT lucaes igeresponsestoexogenousandendogenousallergensinatopicdermatitispatientsunderlongtermsystemiccyclosporineatreatment
AT schmidgrendelmeierp igeresponsestoexogenousandendogenousallergensinatopicdermatitispatientsunderlongtermsystemiccyclosporineatreatment
AT wuthrichb igeresponsestoexogenousandendogenousallergensinatopicdermatitispatientsunderlongtermsystemiccyclosporineatreatment
AT kraftd igeresponsestoexogenousandendogenousallergensinatopicdermatitispatientsunderlongtermsystemiccyclosporineatreatment
AT valentar igeresponsestoexogenousandendogenousallergensinatopicdermatitispatientsunderlongtermsystemiccyclosporineatreatment
AT linhartb igeresponsestoexogenousandendogenousallergensinatopicdermatitispatientsunderlongtermsystemiccyclosporineatreatment